Merck gets FDA nod for delayed-release Noxafil

• The FDA approves Merck's (MRK -0.1%) 100 mg delayed-release Noxafil tablets.
• The product is indicated for "the prophylaxis of invasive Aspergillus and Candida infections." (PR)